60 days ago

Vaccines reduce hospital admissions!! Yay, proof it works!!

Jan from The Wood

From The Lancet. Research report called “Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data”

Lucy A McNamara, PhD *
Ryan E Wiegand, PhD *
Rachel M Burke, PhD *
Andrea J Sharma, PhD *
Michael Sheppard, MS
Jennifer Adjemian, PhD
et al.
Show all authors
Show footnotes
Published:November 03, 2021


The ratio of relative changes comparing the change in the COVID-19 case incidence ratio over the post-vaccine versus pre-vaccine periods showed relative decreases of 53% (95% CI 50 to 55) and 62% (59 to 64) among adults aged 65 to 74 years and 75 years and older, respectively, compared with those aged 50 to 64 years. We found similar results for emergency department visits with relative decreases of 61% (52 to 68) for adults aged 65 to 74 years and 77% (71 to 78) for those aged 75 years and older compared with adults aged 50 to 64 years. Hospital admissions declined by 39% (29 to 48) among those aged 60 to 69 years, 60% (54 to 66) among those aged 70 to 79 years, and 68% (62 to 73), among those aged 80 years and older, compared with adults aged 50 to 59 years. COVID-19 deaths also declined (by 41%, 95% CI –14 to 69 among adults aged 65–74 years and by 30%, –47 to 66 among those aged ≥75 years, compared with adults aged 50 to 64 years), but the magnitude of the impact of vaccination roll-out on deaths was unclear.

The initial roll-out of the US COVID-19 vaccination programme was associated with reductions in COVID-19 cases, emergency department visits, and hospital admissions among older adults.
Read it yourself here….

More messages from your neighbours
7 hours ago

Are you aged 60 years or older? Help us find a way to prevent RSV disease.

Tristan Riley from Southern Clinical Trials Tasman

Older adults are at an increased risk of developing serious complications, including inflammation of the lungs or pneumonia, from respiratory syncytial virus, or RSV. The main goal of the EVERGREEN Study is to see if an investigational study vaccine can prevent RSV disease caused by a respiratory syncytial virus in older adults.

You may be eligible to take part in the study if you are 60 years of age or older, can do your usual daily activities even with some interference from any health conditions, and are able to use smartphone, tablet or computer. Those who qualify may receive the investigational study vaccine and trial-related medical care at no cost and reimbursement for study-related travel expenses.

Participants may receive study-related care throughout the study from a team of experienced doctors and nurses, at our clinic in Stoke.

4 days ago

Wanted to buy - 100 litre (or thereabouts) drum

Clive from Stoke

Either steel or plastic. Doesn't have to be in perfect condition or have lid.
Text 021 076 5136

1 day ago

Exclusive Neighbourly offering!

Climate Insights

Hi Neighbours,

Download your Property Climate Risk Report today and receive a 20% discount! Simply insert this code SUMMER22 at checkout and find out how climate resilient your property is today.

The peak property buying and selling season is here and after the record-breaking warmth of 2021, it is time to consider how our climate could impact your home.

Let's plan together to keep your home cooler, drier and more liveable.
Find out more